|
Age, years
|
51 (23–83)
|
|
Menopausal status
|
|
Pre
|
93 (47.9)
|
|
Post
|
101 (52.1)
|
|
Indication
|
|
New cancer
|
126 (64.9)
|
|
Screening/problem solving
|
68 (35.1)
|
|
Breast density
|
|
Fatty
|
5 (2.6)
|
|
Scattered fibroglandular
|
47 (24.2)
|
|
Heterogeneously dense
|
108 (55.7)
|
|
Dense
|
34 (17.5)
|
|
Background parenchymal enhancement
|
|
Minimal
|
58 (29.9)
|
|
Mild
|
79 (40.7)
|
|
Moderate
|
37 (19.1)
|
|
Marked
|
20 (10.3)
|
|
Lesions per patient
|
|
1 lesion
|
157 (80.9)
|
|
2 lesions
|
30 (15.5)
|
|
3 lesions
|
7 (3.6)
|
|
Lesions (N = 238)
|
|
Largest diameter, cm
|
|
< 1.0 cm
|
98 (41.2)
|
|
1.0–1.9 cm
|
71 (29.8)
|
|
2.0–3.9 cm
|
38 (16.0)
|
|
≥ 4.0 cm
|
31 (13.0)
|
|
Type
|
|
Mass
|
135 (56.7)
|
|
NMLE
|
99 (41.6)
|
|
Focus
|
4 (1.7)
|
|
Delayed phase kinetics(most suspicious)
|
|
Persistent
|
6 (2.5)
|
|
Plateau
|
34 (14.3)
|
|
Washout
|
198 (83.2)
|
|
BI-RADS
|
|
4
|
218 (91.6)
|
|
5
|
20 (8.4)
|
|
Histopathology
|
|
Malignant
|
95 (39.9)
|
|
Benign
|
143 (60.1)
|
|
Cancer subtype (n = 90*)
|
|
Invasive
|
73 (81.1)
|
|
DCIS
|
17 (18.9)
|
|
Benign subtype (n = 143)
|
|
Fibroadenoma
|
25 (17.5)
|
|
Fibrocystic changes
|
21 (14.7)
|
|
Fibrosis
|
14 (9.8)
|
|
Usual ductal hyperplasia
|
12 (8.4)
|
|
Apocrine metaplasia
|
11 (7.7)
|
|
Lobular neoplasia (LCIS, ALH)
|
9 (6.3)
|
|
Papilloma
|
9 (6.3)
|
|
Adenosis
|
8 (5.6)
|
|
Pseudoangiomatous stromal hyperplasia
|
6 (4.2)
|
|
Inflammation
|
5 (3.5)
|
|
Atypical ductal hyperplasia
|
4 (2.8)
|
|
Fibroadenomatoid change
|
4 (2.8)
|
|
Normal breast tissue
|
4 (2.8)
|
|
Other miscellaneous
|
11 (7.7)
|
